Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease)

Kapay Kibadi, Marleen Boelaert, Alexandra G Fraga, Makanzu Kayinua, Adhemar Longatto-Filho, Jean-Bedel Minuku, Jean-Baptiste Mputu-Yamba, Jean-Jacques Muyembe-Tamfum, Jorge Pedrosa, Jean-Jacques Roux, Wayne M Meyers, Françoise Portaels, Kapay Kibadi, Marleen Boelaert, Alexandra G Fraga, Makanzu Kayinua, Adhemar Longatto-Filho, Jean-Bedel Minuku, Jean-Baptiste Mputu-Yamba, Jean-Jacques Muyembe-Tamfum, Jorge Pedrosa, Jean-Jacques Roux, Wayne M Meyers, Françoise Portaels

Abstract

Background: The World Health Organization (WHO) advises treatment of Mycobacterium ulcerans disease, also called "Buruli ulcer" (BU), with a combination of the antibiotics rifampicin and streptomycin (R+S), whether followed by surgery or not. In endemic areas, a clinical case definition is recommended. We evaluated the effectiveness of this strategy in a series of patients with large ulcers of > or =10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC).

Methods: A cohort of 92 patients with large ulcerated lesions suspected to be BU was enrolled between October 2006 and September 2007 and treated according to WHO recommendations. The following microbiologic data were obtained: Ziehl-Neelsen (ZN) stained smear, culture and PCR. Histopathology was performed on a sub-sample. Directly observed treatment with R+S was administered daily for 12 weeks and surgery was performed after 4 weeks. Patients were followed up for two years after treatment.

Findings: Out of 92 treated patients, 61 tested positive for M. ulcerans by PCR. PCR negative patients had better clinical improvement than PCR positive patients after 4 weeks of antibiotics (54.8% versus 14.8%). For PCR positive patients, the outcome after 4 weeks of antibiotic treatment was related to the ZN positivity at the start. Deterioration of the ulcers was observed in 87.8% (36/41) of the ZN positive and in 12.2% (5/41) of the ZN negative patients. Deterioration due to paradoxical reaction seemed unlikely. After surgery and an additional 8 weeks of antibiotics, 98.4% of PCR positive patients and 83.3% of PCR negative patients were considered cured. The overall recurrence rate was very low (1.1%).

Interpretation: Positive predictive value of the WHO clinical case definition was low. Low relapse rate confirms the efficacy of antibiotics. However, the need for and the best time for surgery for large Buruli ulcers requires clarification. We recommend confirmation by ZN stain at the rural health centers, since surgical intervention without delay may be necessary on the ZN positive cases to avoid progression of the disease. PCR negative patients were most likely not BU cases. Correct diagnosis and specific management of these non-BU ulcers cases are urgently needed.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Flow sheet showing process of…
Figure 1. Flow sheet showing process of patient selection and management.

References

    1. World Health Organization. Buruli Ulcer: Progress report, 2004–2008. Weekly Epidemiological Record. 2008;83:145–156.
    1. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol. 2009;27:291–305.
    1. Janssens PG, Pattyn SR, Meyers WM, Portaels F. Buruli ulcer: an historical overview with updating to 2005. Bull Séanc Acad R Sci Outre-Mer. 2005;51:165–199.
    1. Aguiar J, Steunou C. Les ulcères de Buruli en zone rurale au Bénin: prise en charge de 635 cas. Méd Trop. 1997;37:83–89.
    1. Buntine J, Crofts K, editors. World Health Organization. Buruli ulcer. Management of Mycobacterium ulcerans diseases. 2001. 72. World Health Organization. WHO/CDS/CPE/GBUI/2001.3. WHO, Geneva.
    1. Kibadi K. Mycobacterium ulcerans disease (Buruli ulcer): surgical treatment of 102 cases in the Democratic Republic of Congo. Méd Trop. 2005;65:444–448.
    1. Espey DK, Djomand G, Diomande I, Dosso M, Saki MZ, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis. 2002;6:60–65.
    1. Pszolla N, Sarkar MR, Strecker W, Kern P, Kinzl L, et al. Buruli ulcer: A Systemic Disease. Clin Infect Dis. 2003;37:78–82.
    1. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182–3186.
    1. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). 2004. World Health Organization. WHO/CDS/CPE/GBUI/2004.10. Geneva.
    1. Chauty A, Johnson RC. Recommandations de l'OMS pour le traitement de l'Ulcère de Buruli. Bull. 2005;ALLF17:40.
    1. Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51:4029–4035.
    1. Nienhuis W, Stienstra Y, Thompson WA, Awuah P, Abass K, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet. 2010;375:664–672.
    1. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital, Southern Benin, 1997–2001. Emerg Infect Dis. 2004;10:1391–1398.
    1. Phanzu MD, Bafende AE, Dunda KB, Imposo DB, Kibadi AK, et al. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002–2004. Am J Med Hyg. 2006;75:311–314.
    1. Kibadi K, Panda M, Muyembe-Tamfum JJ, Fraga AG, Filho AL, et al. New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis. 2006;14:1790–1792.
    1. Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampin and streptomycin. PloS Negl Trop Dis. 2007;1:e2.
    1. Meyers WM, Connor DH, McCullough B, Bourland J, Moris R, et al. Distribution of Mycobacterium ulcerans infection in Zaïre, including the report of new foci. Ann Soc Belge Méd Trop. 1974;54:147–157.
    1. Eddyani M, Debacker M, Martin A, Aguiar J, Johnson CR, et al. Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semi-solid transport medium. J Clin Microbiol. 2008;46:69–72.
    1. Portaels F, Johnson P, Meyers WM, editors. World Health Organization. Buruli ulcer. Diagnosis of Mycobacterium ulcerans disease. A manual for health care providers. 2001. 92. World Health Organization. WHO/CDS/CPE/GBUI/4. WHO, Geneva.
    1. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol. 1997;35:1696–1700.
    1. Mensah-Quainoo E, Yeboah-Manu D, Asebi C, Patafuor F, Ofori-Adjei D, et al. Diagnostic of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med Int Health. 2008;13:191–198.
    1. Stienstra Y, van der Werf TS, Guarner J, Raghunathan PL, Spotts Whitney EA, et al. Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol. 2003;41:794–797.
    1. Connor DH, Lunn FL. Buruli ulceration, a clinicopathologic study of 38 Ugandans with Mycobacterium ulcerans ulceration. Arch Pathol. 1966;81:183–199.
    1. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis. 2003;9:651–656.
    1. Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol. 1993;46:5–9.
    1. Dodge OG. Mycobacterial skin ulcers in Uganda: histopathologic and experimental aspects. J Pathol Bacteriol. 1964;88:167–174.
    1. O'Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment a result of treatment success, not failure. Med J Aust. 2009;192:564–566.
    1. Johnson PD. Should antibiotics be given for Buruli ulcer. Lancet. 2010;375:618–619.
    1. Chauty A, Pluschke G, Ji B. Preliminary results of a clinical trial of eight-week daily treatment with the combination rifampin-clarithromycin for patients with Buruli ulcer. WHO Annual Meeting on Buruli ulcer, Cotonou, Benin, 31 March–2 April 2009. Abstract book. 2009:42–43.
    1. Nienhuis W, Stienstra Y, Abass KM, et al. Patterns of healing and paradoxical reactions during antimicrobial treatment of Buruli ulcer - Data from the Burulico Drug Trial in Ghana. WHO Annual Meeting on Buruli ulcer, Cotonou, Benin, 31 March–2 April 2009. Abstract book. 2009
    1. Lagarrigue V, Portaels F, Meyers WM, Aguiar J. L'ulcère de Buruli: Attention aux atteintes osseuses! A propos de 33 cas observés au Bénin. Méd Trop. 2000;60:262–266.
    1. Programme National Multisectoriel de Lutte contre le VIH/SIDA (PNMLS), Présidence de la République, République Démocratique du Congo. Rapport national de suivi de la mise en œuvre de la déclaration d'engagement des Chefs d'Etat et de Gouvernement sur le VIH/SIDA (UNGASS), 2007. Publications du PNMLS, 1ère édition, version du 30 janvier 2008. .
    1. Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS. 2008;22:901–902.
    1. Kibadi K, Colebunders R, Muyembe-Tamfum JJ, Meyers WM, Portaels F. Buruli ulcer lesions in HIV-positive patient. Emerg infect Dis. 2010;16:738–739.

Source: PubMed

3
Prenumerera